Hypertension seems to be a disorder that needs consideration for developing a transder

mal drug delivery system (TDDS) because it requires long and continuing therapy. Olmesartan Medoxomil is an antihypertensive medication which has substantial first pass metabolism results in low oral bioavailability. In order to prevent oral complications, the production of elastic vesicles for improving Olmesartan Medoxomil transdermal distribution was the focus of this paper's study. Using a 21.31 full factorial design and a range of edge activators in varying quantities, elastic vesicles formulas were created. The formulae's zeta potential (ZP), particle size (PS), polydispersity index (PDI), entrapment efficiency percentage (EE%), and amount of drug released after six hours (Q6h) were all described. Utilizing Design Expert® software, the ideal formula (F4) was determined, revealing EE% of 81.00±1.22%, PS of 287.30±1.43 nm, PDI of 0.18±0.03, ZP of -39.61±1.10 mV, and Q6h of 47.15±1.10%. The histological investigation verified the safety of the optimum elastic vesicles.